Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q4 2016 call → NOWe need to determine if management conveys that successive engagements of the same kind are coming in at progressively larger size. The transcript mentions various orders, but we need to see if there is a clear statement about escalation of unit size. For example, in Broadcast, they mention a significant multimillion dollar order for IP infrastructure. But is that presented as part of an upward drift? They also mention strong orders, book-to-bill 1.05. But no explicit comparison of deal size over time. For Enterprise, they talk about demand growth, but not deal size. For Industrial, similar. For Network Security, they talk about non-renewal bookings up 29% sequentially, but that's volume, not size per deal. No mention of larger contracts. The only possible is the IP order, but it's described as "a significant multimillion dollar order" and they say "We were excited to win a significant new IP project" but no comparison to past deals. They also say "our customers are beginning to get more comfortable making commitments on new technology" but that's about adoption, not size escalation. No explicit statement that deals are getting bigger. So answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.